Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin.

Abstract

We report the use of a bispecific F(ab')2 antibody to target the ribosome-inactivating protein saporin to the surface antigen CD22 in the treatment of low-grade, end-stage, B-cell lymphoma. Four patients were treated. Toxic effects were minimal (grade I), with mild fever, weakness, and myalgia for 1-2 days after treatment. One patient showed an antibody… (More)

Topics

Cite this paper

@article{French1995TreatmentOB, title={Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin.}, author={Ruth R. French and Terry J. Hamblin and Anthony Bell and Alison L. Tutt and Martin J. Glennie}, journal={Lancet}, year={1995}, volume={346 8969}, pages={223-4} }